Knight Therapeutics Inc. has announced an expansion of its partnership with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte. This amended agreement grants Knight exclusive rights to distribute two innovative biologic products, retifanlimab and axatilimab, in Latin America. Under the partnership, Incyte will handle the development, manufacture, and supply of these medicines, while Knight will focus on obtaining regulatory approvals and distribution in the region. This collaboration builds upon their existing agreement for other treatments, reinforcing Knight's commitment to enhancing its oncology and hematology portfolio in Latin America.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。